Literature DB >> 32583067

The chronological change of indications and outcomes for single-incision laparoscopic cholecystectomy: a Korean multicenter study.

Woohyung Lee1, Young Hoon Roh2, Sung Hwa Kang2, Chung Yun Kim3, YoungRok Choi4, Ho-Seong Han4, Hyung Joon Han5, Tae-Jin Song5, Chang Moo Kang6, Woo Jung Lee6, Sung Hoon Choi7, Sung Yub Jeong7, Tae Ho Hong8, Young Kyoung You8, Jae Hoon Lee1, Ju Ik Moon9, In Seok Choi10.   

Abstract

BACKGROUND: Although single-incision laparoscopic cholecystectomy (SILC) is a common procedure, the change in its surgical indications and perioperative outcomes has not been analyzed.
METHODS: We collected the clinical data of patients who underwent pure SILC in 9 centers between 2009 and 2018 and compared the perioperative outcomes.
RESULTS: In this period, 6497 patients underwent SILC. Of these, 2583 were for gallbladder (GB) stone (39.7%), 774 were for GB polyp (11.9%), 994 were for chronic cholecystitis (15.3%), and 1492 were for acute cholecystitis (AC) (23%). 162 patients (2.5%) experienced complication, including 20 patients (0.2%) suffering from biliary leakage. The number of patients who underwent SILC for AC increased over time (p = 0.028), leading to an accumulation of experience (27.4 vs 23.7%, p = 0.002). The patients in late period were more likely to have undergone a previous laparotomy (29.5 vs 20.2%, p = 0.006), and to have a shorter operation time (47.0 vs 58.8 min, p < 0.001). Male (odds ratio [OR]; 1.673, 95% confidence interval [CI] 1.090-2.569, p = 0.019) and moderate or severe acute cholecystitis (OR; 2.602, 95% CI 1.677-4.037, p < 0.001) were independent predictive factors for gallbladder perforation during surgery, and open conversion (OR; 5.793, 95% CI 3.130-10.721, p < 0.001) and pathologically proven acute cholecystitis or empyema (OR; 4.107, 95% CI 2.461-6.854, p < 0.001) were related with intraoperative gallbladder perforation
CONCLUSION: SILC has expanded indication in late period. In this period, the patients had shorter operation times and a similar rate of severe complications, despite there being more numerous patients with AC.

Entities:  

Keywords:  Acute cholecystitis; Postoperative complication; Single-incision laparoscopic cholecystectomy; Surgical indication

Year:  2020        PMID: 32583067     DOI: 10.1007/s00464-020-07748-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  3 in total

1.  [Laparoscopic cholecystectomy].

Authors:  E Mühe
Journal:  Z Gastroenterol Verh       Date:  1991-03

2.  One-wound laparoscopic cholecystectomy.

Authors:  G Navarra; E Pozza; S Occhionorelli; P Carcoforo; I Donini
Journal:  Br J Surg       Date:  1997-05       Impact factor: 6.939

3.  Relationship of Gallbladder Perforation and Bacteriobilia with Occurrence of Surgical Site Infections following Laparoscopic Cholecystectomy.

Authors:  Nikhar Jain; Sushanto Neogi; Rajandeep Singh Bali; Niket Harsh
Journal:  Minim Invasive Surg       Date:  2015-10-29
  3 in total
  4 in total

1.  Chronological trends in patients undergoing cholecystectomy in Korea: a nationwide health insurance claims study.

Authors:  Chul Hyo Jeon; Jinwook Hong; Jaehun Jung; Jong Youn Moon; Ho Seok Seo
Journal:  Ann Surg Treat Res       Date:  2022-04-05       Impact factor: 1.766

2.  Optimal indication of single-incision laparoscopic cholecystectomy using Konyang Standard Method in benign gallbladder diseases.

Authors:  Seung Jae Lee; In Seok Choi; Ju Ik Moon; Dae Sung Yoon; Won Jun Choi; Sang Eok Lee; Nak Song Sung; Seong Uk Kwon; In Eui Bae; Seung Jae Roh; Sung Gon Kim
Journal:  J Minim Invasive Surg       Date:  2022-09-15

3.  Optimal indication for single-incision laparoscopic cholecystectomy in benign gallbladder diseases.

Authors:  Min-Su Park
Journal:  J Minim Invasive Surg       Date:  2022-09-15

Review 4.  Analogies between medusa and single port surgery in gastroenterology and hepatology: A review.

Authors:  Christof Mittermair; Helmut G Weiss
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.